Y. Lynn Wang, MD, PhD, FCAP


  • Professor, Department of Pathology and Committee on Cancer Biology
  • Director, Lymphoma Translational Pathology
  • Member, Comprehensive Cancer Center


MD Beijing Medical University 1988
PhD, Brandies University 1996
MD, degree conferred, University of the State of New York 2002


Department of Pathology
The University of Chicago
5841 S. Marlyand Ave
MC 1089, Room N 316A
Chicago, IL 60637


hone: (773) 702-4397

Pathology Website: http://pathology.uchicago.edu/directory/y-lynn-wang-md-phd-fcap


•         Understand the role of signal transduction pathways in the pathogenesis of lymphoid malignancies (DLBCL, CLL and MCL)

•         Define the functional consequences of pathway perturbation with novel agents and genetic knockdown

•         Define the mechanisms of cellular sensitivity and resistance to such perturbations using advanced technologies including next-gen sequencing, RNA-Seq and FlowSight

•         Eventual goal: Identify new candidates or new combination strategies for molecularly targeted therapy and improve patients’ response

As a physician-scientist and the Director of Lymphoma Translational Pathology, Dr. Wang is the principal investigator of several translational research projects on aberrant signal transduction pathways in B-cell lymphoma and leukemia. The Wang lab is one of the pioneers who explored the idea of targeting BCR signaling in lymphoid malignancies before BCR-directed therapies became well-known and successful.  Using inhibitors of LYN, SYK and BTK, the lab has demonstrated the critical role of BCR signaling in lymphoma cell proliferation and survival in diffuse large B cell lymphoma (DLBCL), CLL and mantle cell lymphoma. Their work on dasatinib response prediction in DLBCL has led to the successful development of a Phase II clinical trial at Weill Cornell where she worked.

Dr. Wang’s work on B-cell receptor signaling and BCR-targeted therapies has extended to the characterization of the molecular mechanisms underlying drug sensitivity and resistance. In particular, the Wang lab contributed significantly to the understanding of the mechanisms leading to primary and secondary resistance to SYK and BTK inhibition. In May 2014, the lab reported their discovery of BTKC481S mutation in a CLL patient with ibrutinib (a BTK inhibitor) resistance in the NEJM. [UC News Release on Dr. Wang's work on ibrutinib resistance in CLL] That was followed by several studies elucidating the molecular mechanisms of primary and secondary resistance to ibrutinib in CLL and MCL.

Projects in Wang Lab involve a variety of molecular, cellular, immunological, biochemical, pharmacological and genomic techniques, providing a good opportunity for learning. Many of these projects engage collaborations with other scientists, pathologists and heme/onc physicians at home and outside institutions, as well as with industrial partners. Dr. Wang is a well accomplished investigator who has authored or co-authored 63 original scientific publications.  She has given >70 invited extramural oral presentations.  She serves as a consultant/key-opinion leader for several diagnostic and pharmaceutical companies.

Research Papers in PubMed